Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leiomyosarcoma 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostate Cancer Metastatic 1Mesothelioma, Malignant 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × rucaparib × Clear all
NCT04171700 2023-10-02

LODESTAR

pharmaand GmbH

Phase 2 Terminated
83 enrolled 16 charts
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03140670 2023-09-28

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Abramson Cancer Center at Penn Medicine

Phase 2 Terminated
46 enrolled 16 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02042378 2023-06-13

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

pharmaand GmbH

Phase 2 Completed
19 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡